Companies › MicuRx
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 4; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Contezolid Bacterial 70S ribosome inhibitor | DARS | Phase 3 | Diabetic Foot Infection; Mycobacterium Avium Complex Pulmonary Disease; Pulmonary Tuberculosis | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06081361 | Contezolid | Phase 3 | Pulmonary Tuberculosis | Infectious disease | Dec 2026 |
| NCT05369052 | Contezolid | Phase 3 | Diabetic Foot Infection | Infectious disease | Jun 2027 |
| NCT07084402 | Contezolid | Phase 4 | Mycobacterium Avium Complex Pulmonary Disease | Infectious disease | Jul 2027 |
| NCT07213765 | Contezolid | Phase 4 | Mycobacterium Avium Complex Pulmonary Disease | Infectious disease | Sep 2028 |
–
Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Jiangxi Qingfeng Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.